TY - JOUR
T1 - Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis
AU - Menge, T.
AU - Schloot, N. C.
AU - Schott, M.
AU - Hemmer, B.
AU - Wiendl, H.
AU - Roden, M.
AU - Hartung, H. P.
AU - Kieseier, B. C.
N1 - Funding Information:
Supported by the EU project NABinMS. T.M. was funded in part by the Forschungsförderungsfonds, Heinrich-Heine University, Germany.
Funding Information:
Disclosure: Dr. Menge has received honoraria and travel support from Bayer Schering Pharma, Biogen Idec, and Merck Serono. Dr. Schloot receives honoraria from Andromeda Ltd., Pfizer, Bayhill, Astra Zeneca, and Sensile Medical. Prof. Schott reports no disclosures. Prof. Hemmer has received honoraria and grant support from Bayer Schering Pharma, Merck Serono, Biogen Idec, Teva, Rosche, Genzyme, Genentech, and Novartis. Prof. Wiendl has received honoraria for lecturing and travel expenses for attending meetings and received financial research support from Bayer Schering, Biogen Idec, Sanofi-Aventis, Schering, Merck Serono, and Teva Pharmaceutical, and serves or has served as consultant for Serono, Medac, Sanofi-Aventis, Teva Pharmaceutical, Biogen Idec, and Bayer Schering Pharma. Prof. Roden reports no disclosures. Prof. Hartung has received honoraria, with approval of the Rector and the CEO of Heinrich Heine University, for consulting and speaking from Bayer Schering Pharma, Biogen Idec, Merck Serono, and Teva Pharmaceutical. Prof. Kieseier has received honoraria for lecturing, travel expenses for attending meetings, and received research support from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, and Teva Pharmaceutical, and serves or has served as consultant for Biogen Idec, Medac, Sanofi-Aventis, and Teva Pharmaceutical.
PY - 2009/9
Y1 - 2009/9
N2 - Indications:83 patients with multiple sclerosis.Patients:209 patients. IFNβ group negative for neutralizing antibodies (NABs): n=106, 75 females and 31 males, mean age 40.7 years, 47 received Extavia. IFNβ group with positive NABs: n=103, 69 females and 34 males, mean age 41.7 years, 36 received Extavia. Control group (no treatment): n=57, 41 females and 16 males, mean age 39.5 years.TypeofStudy:A study evaluating whether interferon (IFN) beta (including Extavia) treatment induce organ-specific autoantibodies (AAbs) in patients with multiple sclerosis (MS).DosageDuration:Dosage not stated. Mean duration: 46.1 months for patients with negative NABs and 41.4 months for those with positive NABs.Results:When stratified for the presence of NABs, prevalences for neither anti-GAD65, anti-TPO, nor anti-Tg were remarkably elevated in any of the subgroups. Titers of positive AAbs were not remarkably different between subgroups for anti-GAD65, anti-TPO, or anti-Tg, even though positive AAbs were highly elevated in the majority of cases (median anti-GAD65: 28.1 U/mL; anti-TPO: 288.7 U/mL). Gender was a confounding factor for anti-TPO and anti-Tg, being more prevalent in females (anti-TPO: 89% versus 67%; anti-Tg: 90% versus 68%). Age was also a confounder: anti-TPO positive patients were older (44.7 versus 40.3 years) and anti-GAD65 seropositive patients younger (32.0 versus 41.0 years). Expanded Disability Status Scale, disease duration, or IFNβ product were not associated with either AAbs status.AdverseEffects:No adverse events were mentioned.AuthorsConclusions:Our results underscore the longstanding safety profile of IFNβ therapy in MS, especially in light of upcoming immunotherapies that may convey the potential to induce autoimmunity, e.g., autoimmune thyroiditis.FreeText:AAbs were determined by commercial radioligand assays against glutamic acid decarboxylase (GAD65) and against thyroperoxidase (TPO) and thyroglobulin (Tg) with predefined cutoff levels. Presence of NABs was assessed by capture enzyme linked immunosorbent assay and ex vivo myxovirus resistance protein A real time polymerase chain reaction.
AB - Indications:83 patients with multiple sclerosis.Patients:209 patients. IFNβ group negative for neutralizing antibodies (NABs): n=106, 75 females and 31 males, mean age 40.7 years, 47 received Extavia. IFNβ group with positive NABs: n=103, 69 females and 34 males, mean age 41.7 years, 36 received Extavia. Control group (no treatment): n=57, 41 females and 16 males, mean age 39.5 years.TypeofStudy:A study evaluating whether interferon (IFN) beta (including Extavia) treatment induce organ-specific autoantibodies (AAbs) in patients with multiple sclerosis (MS).DosageDuration:Dosage not stated. Mean duration: 46.1 months for patients with negative NABs and 41.4 months for those with positive NABs.Results:When stratified for the presence of NABs, prevalences for neither anti-GAD65, anti-TPO, nor anti-Tg were remarkably elevated in any of the subgroups. Titers of positive AAbs were not remarkably different between subgroups for anti-GAD65, anti-TPO, or anti-Tg, even though positive AAbs were highly elevated in the majority of cases (median anti-GAD65: 28.1 U/mL; anti-TPO: 288.7 U/mL). Gender was a confounding factor for anti-TPO and anti-Tg, being more prevalent in females (anti-TPO: 89% versus 67%; anti-Tg: 90% versus 68%). Age was also a confounder: anti-TPO positive patients were older (44.7 versus 40.3 years) and anti-GAD65 seropositive patients younger (32.0 versus 41.0 years). Expanded Disability Status Scale, disease duration, or IFNβ product were not associated with either AAbs status.AdverseEffects:No adverse events were mentioned.AuthorsConclusions:Our results underscore the longstanding safety profile of IFNβ therapy in MS, especially in light of upcoming immunotherapies that may convey the potential to induce autoimmunity, e.g., autoimmune thyroiditis.FreeText:AAbs were determined by commercial radioligand assays against glutamic acid decarboxylase (GAD65) and against thyroperoxidase (TPO) and thyroglobulin (Tg) with predefined cutoff levels. Presence of NABs was assessed by capture enzyme linked immunosorbent assay and ex vivo myxovirus resistance protein A real time polymerase chain reaction.
UR - http://www.scopus.com/inward/record.url?scp=70349570577&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e3181b78460
DO - 10.1212/WNL.0b013e3181b78460
M3 - Article
C2 - 19752459
AN - SCOPUS:70349570577
SN - 0028-3878
VL - 73
SP - 900
EP - 902
JO - Neurology
JF - Neurology
IS - 11
ER -